Tenax Therapeutics price target raised to $34 from $25 at Guggenheim

Guggenheim raised the firm’s price target on Tenax Therapeutics (TENX) to $34 from $25 and keeps a Buy rating on the shares. ahead of the Phase 3 LEVEL readout, the timing of which was recently narrowed to Q3 from the second half of 2026. The firm views continued clinical execution as “encouraging” as the company advances toward the “pivotal and potentially practice-changing” LEVEL study readout, the analyst tells investors.